硼替佐米耐药多发性骨髓瘤中循环miRNA生物标志物的预后、诊断和治疗的主题分析
A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma.
作者信息
Bamfield-Cummings Shafisha, Silva Jeane, Karim Zubair A
机构信息
Department of Health Management, Economics, and Policy, Augusta University, GA, USA.
Department of Nutrition and Dietetics, College of Allied Health Science, Augusta University, GA, USA.
出版信息
SAGE Open Med. 2025 Apr 26;13:20503121251328486. doi: 10.1177/20503121251328486. eCollection 2025.
OBJECTIVE
The increasing demand for precision medicine has spurred molecular diagnostic investigations to emphasize the utility of miRNA as significant biomarkers. Recent studies have underscored miRNA's role as prognostic, diagnostic, and therapeutic biomarkers in managing and monitoring multiple myeloma patients. This review aims to present the latest insights on the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers in bortezomib-resistant multiple myeloma.
METHODS
For this purpose, a comprehensive thematic literature review from January 2014 and August 2024 was conducted utilizing the databases CINAHL, Pubmed, and Google Scholar. Twenty pertinent studies were meticulously analyzed and categorized into the following sections: Bortezomib (BTZ) resistance in multiple myeloma, the predictive role of miRNAs in BTZ resistance, the impact of circulating miRNAs in multiple myeloma, and the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers.
RESULTS
Of note, eight studies identified circulating miRNAs as diagnostic miRNA biomarkers (i.e., miR-744, miR-130a, let-7d, let-7e, miR-34a, etc.). In comparison, nine studies identified several circulating miRNAs that can be used as prognostic biomarkers (i.e., miR-20a, miR-483-5p, mir-1246, let-7a, let-7e, etc.). Moreover, five studies identified circulating miRNAs as promising therapeutic biomarkers (i.e., mir-15a, mir-92a, mir-19a, etc.). This discovery can significantly enhance early detection, accurate diagnosis, prognosis, overall survival rates, and quality of life for patients with multiple myeloma.
CONCLUSION
Based on this evidence, exploring circulating miRNAs as a potential noninvasive biomarker for multiple myeloma represents a noteworthy advancement. This is attributed to the abundance of miRNAs in plasma or serum, which exhibits remarkable stability against enzymatic degradation.
目的
对精准医学的需求不断增加，促使分子诊断研究强调微小RNA（miRNA）作为重要生物标志物的效用。最近的研究强调了miRNA在多发性骨髓瘤患者的管理和监测中作为预后、诊断和治疗生物标志物的作用。本综述旨在介绍循环miRNA作为硼替佐米耐药多发性骨髓瘤的预后、诊断和治疗生物标志物的最新见解。
方法
为此，利用CINAHL、PubMed和谷歌学术数据库对2014年1月至2024年8月的文献进行了全面的主题综述。对20项相关研究进行了细致分析，并分为以下几个部分：多发性骨髓瘤中的硼替佐米（BTZ）耐药性、miRNA在BTZ耐药性中的预测作用、循环miRNA在多发性骨髓瘤中的影响以及循环miRNA作为预后、诊断和治疗生物标志物的潜力。
结果
值得注意的是，八项研究将循环miRNA鉴定为诊断性miRNA生物标志物（即miR-744、miR-130a、let-7d、let-7e、miR-34a等）。相比之下，九项研究确定了几种可作为预后生物标志物的循环miRNA（即miR-20a、miR-483-5p、mir-1246、let-7a、let-7e等）。此外，五项研究将循环miRNA鉴定为有前景的治疗生物标志物（即mir-15a、mir-92a、mir-19a等）。这一发现可显著提高多发性骨髓瘤患者的早期检测、准确诊断、预后、总生存率和生活质量。
结论
基于这一证据，探索循环miRNA作为多发性骨髓瘤潜在的非侵入性生物标志物是一项值得关注的进展。这归因于血浆或血清中miRNA的丰富性，其对酶降解具有显著的稳定性。
Zotero 插件